Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Bayer buys cell therapy investment BlueRock for up to $600mm

Executive Summary

Bayer AG fully acquired privately held cell therapeutics developer BlueRock Therapeutics, paying $240mm in cash up front for 59.2% of the company it did not already own, and pledging another $360mm in development milestones. Including Bayer’s previous investment, BlueRock is valued at $1bn.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Acquisition of Private Biotech
    • Includes Earnout
    • Partial Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register